Results 141 to 150 of about 21,951,536 (341)
The bcl-2 oncogene in Hodgkin's disease arising in the setting of follicular non-Hodgkin's lymphoma [PDF]
DP LeBrun+5 more
openalex +1 more source
This work identifies a novel mechanism by which dopamine D1 receptor (DRD1) contributes to the pathogenesis of glucocorticoid (GC)‐associated osteonecrosis of the femoral head (ONFH) through the regulation of osteoblastic apoptosis, indicating that DRD1 serves as a critical mediator of the crosstalk between the nervous and skeletal systems.
Kai Zheng+11 more
wiley +1 more source
The Bcl-2 family of proteins: regulators of cell death and survival [PDF]
Gabriel Nuñez, Michael F. Clarke
openalex +1 more source
Inspired by the structural and functional characteristics of bone, bionic nanomaterials combined with nanotechnology can more accurately replicate stem cell niches, enabling the design of bone tissue engineering scaffolds with diverse nanoscale properties to promote stem cell migration, proliferation, and differentiation. This precise control over stem
Yangfan Pei+11 more
wiley +1 more source
Bcl‐2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF‐κB by TNF [PDF]
Hugo Albrecht+2 more
openalex +1 more source
Cisplatin causes reactive oxygen species accumulation, leading to apoptosis and inflammation in cochlear hair cells. Small extracellular vesicles primarily derived from the damaged hair cells likely contribute to cisplatin‐induced ototoxicity, carrying a variety of microRNAs and proteins.
Jingru Ai+14 more
wiley +1 more source
Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. [PDF]
Mildred Lam+5 more
openalex +1 more source
Acute restraint stress enhances STAT3Ser727 phosphorylation in dopaminergic neurons in mice. This modification promotes the upregulation of GABBR2 and GABRB3, reduces neuronal activity, and contributes to anxiety‐like behavior and diminished reward‐seeking following stress exposure.
Mingshuo Shao+10 more
wiley +1 more source
BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC). Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) induces dose-limiting thrombocytopenia through on-target BCL-xL inhibition in ...
Sajid Khan+7 more
doaj +1 more source
bcl-2 Protein in Non-Small-Cell Lung Carcinoma [PDF]
Francesco Pezzella+8 more
openalex +1 more source